People

Frank D'Amelio is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Former St. Jude Children’s Research Hospital researcher who analyzes customer feedback and market data.

Works in program development, training and vocational guidance for people with neurological differences. Previously implemented programs at SAP, UP Michigan Works! and SpArc Philadelphia.

Leads operations across countries and time zones, drawing on experience in call-center management and sales.

Previously managed software engineering teams building healthcare and consumer products, with a specialization in data engineering.

Co-founded Daivergent after working in behavioral healthcare as a data scientist, consultant and researcher. Holds a BA from Harvard University and an MS in Epidemiology from Johns Hopkins.

Visually impaired Danish craftsman whose idea for volunteer video assistance led to Be My Eyes.

Marketing executive with experience in international growth, brand development, business transformation and marketing operations.

Pia Leonhard is Head of Finance & Operations (Maternity Leave) at Discovery Ventures. The current firm directory states: Pia Leonhard Head of Finance & Operations (Maternity Leave) DataGuard, Ciao Bella, Zeitgold.

Joel Stead is a director of Stead Impact Ventures. He held sales, marketing and customer service leadership roles during 18 years at Seagate Technology and established the University of Minnesota Carlson School of Management Leadership Lab.

Sandra Hirsch is Executive Assistant at Discovery Ventures. The current firm directory states: Sandra Hirsch Executive Assistant.

Jay Stead is a director of Stead Impact Ventures and an adviser to software and technology businesses. He formerly led Sagebrush Corporation and held executive roles at Reynolds and Reynolds, with philanthropic interests in healthcare, education and innovation.

Hannes Streeck is Operator in Residence at Discovery Ventures. The current firm directory states: Hannes Streeck Operator in Residence Managing Director - Fiege CEO - Fiege Far East.

Sandy Rosenberg is Senior Advisor at Stead Impact Ventures and founder of Discus Ventures, supporting company development and capital strategy. He previously worked in Citigroup investment banking and serves as an executive in residence and adjunct professor at Tufts University’s Gordon Institute.

Jacquee Nickerson is Executive Assistant at Stead Impact Ventures, supporting its leadership and portfolio companies. Her background includes administration across legal, engineering, manufacturing and mental health organizations, an MBA and project management certification.

Benjamin Schickert is Operating Partner & CFO at Discovery Ventures. The current firm directory states: Benjamin Schickert Operating Partner & CFO Founder - Myos Morgan Stanley, Allianz.

Aidan Thompson is Chief Commercial Officer of Stead Impact Ventures, advising portfolio companies on market entry, revenue growth and exit preparation. He has healthcare technology executive experience and a doctorate in neuroscience and biomechanics. Aidan Thompson serves on the Board of Directors of MedWatch Technologies, following Stead Impact Ventures’ financing announcement. He is Chief Commercial Officer of Stead Impact Ventures.

Tobias Weiper is Partner at Discovery Ventures. The current firm directory states: Tobias Weiper Partner Co-Founder - VATION Co-Founder - evopark.

Dana Larson is Chief Marketing Officer of Stead Impact Ventures, supporting portfolio positioning, customer journeys and growth marketing. Her experience spans technology companies, cultural organizations and University of Iowa fundraising campaigns.

Tiffani Shaw is CEO of Stead Impact Ventures. She previously served as Clarivate chief of staff and as executive vice president and COO of the University of Iowa Center for Advancement, following financial and operational leadership roles.

Stefan Jeschonnek is General Partner at Discovery Ventures. The current firm directory states: Stefan Jeschonnek General Partner Co-Founder - Zeitgold Co-Founder - SumUp.

Jan Deepen is General Partner at Discovery Ventures. The current firm directory states: Jan Deepen General Partner Co-Founder - Zeitgold Co-Founder - SumUp.

Dean Zhao is published in Ostendo Technologies' current leadership directory with responsibility for board director.

Barak Bussel is a Board Director of Ostendo Technologies. The company's current directory identifies him as a Principal of Third Wave Ventures.

Doug Pierce is published in Ostendo Technologies' current leadership directory with responsibility for accounting and financial reporting.

Weilong Tang is published in Ostendo Technologies' current leadership directory with responsibility for semiconductors engineering.

Babak Razi serves in Strategy and on the Board of Directors of Ostendo Technologies. Its current board directory also identifies him as a Principal of Third Wave Ventures.

Dale McNeil is published in Ostendo Technologies' current leadership directory with responsibility for system engineering.

Jason McDowall is published in Ostendo Technologies' current leadership directory with responsibility for research & development.

David Behzadi is published in Ostendo Technologies' current leadership directory with responsibility for business development & manufacturing and board director.

Chih-li Chuang is published in Ostendo Technologies' current leadership directory with responsibility for product engineering.

Hussein S. El-Ghoroury is Founder, Chairman and Chief Executive Officer of Ostendo Technologies. A mobile and telecommunications entrepreneur, he previously served as CTO of IBM Microelectronics, President and CEO of CommQuest Technologies and Senior Vice President of Linkabit. He earned MS and PhD degrees in electrical engineering from Southern Methodist University.

Jennifer Temel is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Clinical Director of Thoracic Oncology Co-Director, Cancer Outcomes Research and Education Program Professor of Medicine at Harvard Medical School; that title is context, not an executive position at Thyme Care.

Ramy Sedhom is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Assistant Professor, Hematology & Oncology, University of Pennsylvania; that title is context, not an executive position at Thyme Care.

Robert Young advises Spinogenix on science. A medicinal chemist, he previously led drug-discovery groups at Merck in Montreal and the UK before joining Simon Fraser University. His work has included neuroscience, asthma and arthritis drug development.

Ravi Parikh is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Associate Professor and Director of the Human-Algorithm Collaboration Lab (HACLab), Emory University; that title is context, not an executive position at Thyme Care.

Thomas Leblanc is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Associate Professor of Medicine, Duke University School of Medicine; that title is context, not an executive position at Thyme Care.

Steven Arnold advises Spinogenix on science and studies Alzheimer’s disease and translational biomarkers. He is a Harvard neurologist based at Massachusetts General Hospital and previously led memory and Alzheimer’s research programs at Penn.

Ethan Basch is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Physician-in-Chief of the North Carolina Cancer Hospital, Chief of Oncology and distinguished professor in Medical Oncology and Health Policy & Management at the University of North Carolina; that title is context, not an executive position at Thyme Care.

Joseph Coyle advises Spinogenix on science. His research and academic leadership span developmental neurobiology, glutamate signaling and psychiatric disease, including psychiatry and neuroscience appointments at Harvard and Johns Hopkins.

Lalan Wilfong is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Chief Medical Officer, Navista; that title is context, not an executive position at Thyme Care.

Jeff Vacirca is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as CEO, New York Cancer & Blood Specialists; that title is context, not an executive position at Thyme Care.

Steven (Steve) Young serves on Spinogenix’s board. The former NFL quarterback co-founded private-equity firm HGGC and the Forever Young Foundation. He is distinct from Cambridge AI researcher and Amadeus venture partner Steve Young.

Stephen Schleicher is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Medical Oncologist, Tennessee Oncology; that title is context, not an executive position at Thyme Care.

Alti Rahman is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Chief Strategy and Innovation Officer, American Oncology Network; that title is context, not an executive position at Thyme Care.

Samyukta Mullangi is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as VP Clinical Strategy, OpenEvidence; that title is context, not an executive position at Thyme Care.

Kathy Giusti is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Co-Founder and Board Director of the MMRF; that title is context, not an executive position at Thyme Care.

Sasha Damouni Ellis leads investor relations for Spinogenix and is a founding partner of Damouni Group. Her earlier corporate-affairs and investor-relations leadership includes Vir Biotechnology. Her company role is recorded without implying exclusive employment.

Bob Badal is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Co-Founder & Chief Revenue Officer, Strive Health; that title is context, not an executive position at Thyme Care.

Ryan MacDonald is Spinogenix’s chief business officer. His earlier corporate-development and finance roles include Bristol Myers Squibb, Novavax and Pfizer, covering acquisitions, licensing, divestitures and capital markets.

Sharron Gargosky leads development at Spinogenix. A biochemist with international drug-development experience, she has overseen regulatory, manufacturing, nonclinical, clinical and medical-affairs work across small molecules, biologics, diagnostics and cellular therapies.

Puneet Singh is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as CEO, CareBridge; that title is context, not an executive position at Thyme Care. Puneet Singh is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: CEO, Quartet Health; Chief Growth Officer, Anthem Diversified Business Group. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Craig Erickson is Spinogenix’s chief medical adviser and a translational researcher in neurodevelopmental disorders. His work at Cincinnati Children’s includes patient-level measures of brain target engagement and precision approaches to evaluating investigational therapies.

Peter Vanderklish is Spinogenix’s chief science officer. His research concerns synaptic plasticity, dendritic spines and the molecular mechanisms of neurological conditions, including Fragile X syndrome. His graduate training was at UC Irvine.

Alyssa Reisner is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Lead Director and Investment Principal, CVS Health® Ventures; that title is context, not an executive position at Thyme Care. Alyssa Reisner is a General Partner leading early- and mid-stage investments for CVS Health Ventures’ dedicated corporate fund. She studied at Babson College and has worked across CVS enterprise strategy and digital functions, including transactions in specialty care, nutrition, women’s and behavioral health. Her current manager title is separate from the older Lead Director and Investment Principal wording in Thyme Care’s observer biography.

Vijay Patel is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Managing Partner, CVS Health® Ventures; that title is context, not an executive position at Thyme Care. Vijay Patel is Managing Partner of CVS Health Ventures, overseeing direct venture investing, minority growth equity, limited-partner investments and market development. He previously led enterprise business development and digital-health partnerships after joining CVS’s Boston Digital Innovation Lab in2015, and earlier invested at H.I.G. Growth Partners and Bain Capital. He holds a University of Pennsylvania Management and Technology bachelor’s degree and an MIT Sloan MBA.

James Olsen is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Founder & Managing Partner, Concord Health Partners; that title is context, not an executive position at Thyme Care.

Bill Frist is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Co-Founder & Partner, Frist Cressey Ventures; that title is context, not an executive position at Thyme Care. Bill Frist is publicly named in Despierta’s combined advisors and select limited partners roster. The source does not distinguish this individual’s advisory or LP capacity, identify a commitment amount, or supply a substantive biography; its generic image and placeholder biography are excluded. The affiliation is recorded with this explicit limitation. Bill Frist is the physician and former US Senate majority leader identified as William H. Frist in BehaVR’s December 2020 SEC director schedule. The company affiliation is historical and does not imply a personal investment. His own biography confirms his cardiac and heart-lung transplant surgical career and subsequent healthcare investment leadership.

Brenton Fargnoli is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Partner, Lightspeed Venture Partners; that title is context, not an executive position at Thyme Care.

Elizabeth Canis is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as COO, Wellvana & Executive Advisor, Foresite Capital; that title is context, not an executive position at Thyme Care.

Brian Belsky is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Managing Director, Concord Health Partners; that title is context, not an executive position at Thyme Care.

Robin Shah co-founded Thyme Care in2020 and became executive chairman effective September1,2026 after serving as CEO. He focuses on expansion through Thyme Companies, the newly announced parent of the Thyme businesses.

Jesse Waldron is publicly listed by Thyme Care as Chief Financial Officer.

Scott Voigt is publicly listed by Thyme Care as SVP, Product.

Rob Rodkey is publicly listed by Thyme Care as SVP, Engineering.

Etan Raskas is publicly listed by Thyme Care as VP, Business Development and Operations.

Ashley Patton is publicly listed by Thyme Care as VP, Thyme Care Oncology Partners.

Nikkayla Page is publicly listed by Thyme Care as VP, Marketing & Communications.

Michael Markowicz is publicly listed by Thyme Care as Chief Legal Officer.

Marcia Macphearson is publicly listed by Thyme Care as Chief Operating Officer.

Nicki MacManus is publicly listed by Thyme Care as GM, Clinical Trials.

Jeff Lovesy is publicly listed by Thyme Care as SVP and GM of Commercial Partnerships.

Mark Lombardi is publicly listed by Thyme Care as SVP, Provider Partnerships.

Chris Lau is publicly listed by Thyme Care as VP, Health Economics.

Alphan Kirayoglu is publicly listed by Thyme Care as SVP, Data Science.

Ahsan Khan is publicly listed by Thyme Care as Deputy General Counsel.

Jessa Kelley is publicly listed by Thyme Care as Chief of Staff.

Julia Ivanova is publicly listed by Thyme Care as SVP, Growth and Value-Based Partnerships.

Bobby Green is a medical oncologist who co-founded Thyme Care in2020 and remains its president and chief medical officer and a board member. Bobby Green is listed in Thyme Care’s public medical-provider directory as Oncologist. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Julia Frydman is publicly listed by Thyme Care as VP, Clinical Outcomes. Julia Frydman is listed in Thyme Care’s public medical-provider directory as Palliative Care Physician. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Ross Feinstein is publicly listed by Thyme Care as Head of AI Platform.

Manya Ellenberg is publicly listed by Thyme Care as SVP, People.

Brian Dorsey is publicly listed by Thyme Care as SVP, Clinical Innovation and Delivery Design. Brian Dorsey is listed in Thyme Care’s public medical-provider directory as Complex Care Physician. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Head of Engineering at Davidovs Venture Collective. Engineer with founder experience and earlier DoorDash, Cherry Labs and VK work. Builds AI agents, automated workflows, data integrations and the fund platform backend.

Head of Investor Relations and Community at Davidovs Venture Collective, responsible for investor relations and back-office operations. Previously worked with the Davidovs in startup operations, event and community management. Primary personal repost confirms the AI Fund completed its first close.

Head of Product at Davidovs Venture Collective, leading product management and analytics operations. Repeat founder with an exit; helped develop Seed Fund automation.

Venture Partner at Davidovs Venture Collective working across its Seed and AI funds, and active Seed Fund LP and Deal Captain. Own biography describes product work at Meta and earlier Perplexity, Google and MetaArcade experience; prior affiliations are not additional DVC employment roles.

General Partner at Davidovs Venture Collective focused on its AI Fund, and active Seed Fund LP and Deal Captain. Founder of FrontPage, acquired by Microsoft, experienced investor and Academy Award-winning filmmaker.

General Partner at Davidovs Venture Collective focused on its AI Fund. Prior startup experience at IMVU and corporate development, product management and governance experience at Yahoo and Google. Previously a naval officer on a nuclear submarine.

Founder and Managing Partner of Davidovs Venture Collective, focused on investments and portfolio management. Repeat AI founder and investor, co-founder of Cherry Labs and Gagarin Capital, with earlier iTech Capital and MSQRD experience. Personal historical investments and prior firm investments are separate from DVC institutional checks.

Founder and Managing Partner of Davidovs Venture Collective. Former AI startup founder and operator at Humanism.is and Cherry Labs and investor at Gagarin Capital. Leads DVC strategy, investment process, internal products and community.

Brad Diephuis is a primary care physician and CEO of Thyme Care, effective September 1, 2026. Previously its president and COO, he joined in2022 as chief business officer after advising the Center for Medicare and Medicaid Innovation. Brad Diephuis is a primary care physician and CEO of Thyme Care, effective September 1, 2026. Previously its president and COO, he joined in2022 as chief business officer after advising the Center for Medicare and Medicaid Innovation.

Nate Brown is publicly listed by Thyme Care as SVP, Market Operations. Nate Brown is publicly listed by Thyme Care as SVP, Market Operations.

Heidi Spitz is Head of Revenue Operations at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Craig Irwin is Vice President of Sales at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Atai Barkai is Co-Founder and Chief Executive Officer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

David McKay is Head of Forward Deployed Engineering at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Alex Clarke is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Martha Schumann is Software Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Cham Española is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Precious Aprille Plata is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Dustin Clark is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Josh Gordon is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Jerel Velarde is Staff Applied AI Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Mark Fogle is Lead, Partnerships and Integrations at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Benjamin Taylor is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Anmol Baranwal is Technical Writer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Austin Merrick is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Lukas Moschitz is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Alem Tuzlak is Software Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Maxim Zubarev is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position. His own website identifies CopilotKit as a previous client; retain this as a technical collaboration rather than asserting current salaried employment.

Mike Ryan is Principal Architect at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Sam Julien is Director of Product at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Sofía Sánchez-Zárate is Head of Technical Ecosystems at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Eli Berman is Growth Team at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Nathan Tarbert is Community and Developer Relations at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Maximiliano Korp is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Ran Shem Tov is Founding Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Markus Ecker is Software Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Tyler Slaton is Founding Engineer and Head of Open Source at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Travis Murdock is Head of Go-To-Market at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Jordan Ritter is Chief Technology Officer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications. He publicly announced joining as CTO in May2026 after previously mentoring and advising its founders. He co-founded Napster.

Uli Barkai is Co-Founder and Head of Growth at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications. He co-founded the company with his brother Atai. The investor portfolio uses the CMO title; published current reporting describes his growth leadership.

Manuel E. Cortés Rada is publicly affiliated with Fundamental Research Labs on his current self-published professional profile and contributed to its Project Sid multi-agent research. A specific current job title is not publicly disclosed in the retrieved profile.

Peter Y. Wang is a founding scientist at Fundamental Research Labs, formerly Altera.AL, working on AI agents. The company’s 2024 welcome identifies prior Stanford postdoctoral neuroscience research in Karl Deisseroth’s laboratory, a Columbia neuroscience PhD in Richard Axel’s laboratory and a Google X AI residency. His current self-profile retains the Altera affiliation. He is distinct from Anaconda co-founder Peter Wang.

Felix Wong is Chief Technology Officer at Fundamental Research Labs. The recruiting firm that placed him identifies his CTO appointment, and his own current profile identifies the company. He previously led engineering for Snap’s My AI and worked on Meta Messenger.

Nico Christie co-founded Fundamental Research Labs, formerly Altera.AL, and created its Shortcut Excel AI product. He was identified as Chief Business Officer at the 2024 launch. His own 2026 announcement says he stepped away from the FRL and Shortcut operating team; he is not represented as a current operating executive.

Andrew Ahn is a co-founder of Fundamental Research Labs, formerly Altera.AL, publicly identified as Chief Science Officer at its 2024 launch. He earned a mathematics PhD at MIT in 2020. His identity matches the mathematician’s Cornell profile, distinct from other people with the same name.

Shuying Luo is a co-founder and the founding CTO of Fundamental Research Labs, formerly Altera.AL. Her current public work includes model training and infrastructure for the Pivot0.5 spreadsheet and finance model. Founding CTO is a historical title; Felix Wong subsequently joined as CTO.

Guangyu Robert Yang is co-founder and CEO of Fundamental Research Labs, formerly Altera.AL. A computational neuroscientist and former MIT faculty member, he leads research and products involving autonomous and collaborative AI agents.

Vice President of Business Development of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Chief Commercial Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Chief Operating Officer and Chief Financial Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Chief Technology Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Chief AI Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Chief Executive Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Co-founder and distinguished technologist at Flexcompute, a researcher in photonics and computational electromagnetics. The company team page lists a PhD in physics from MIT and National Academy of Engineering membership.

Co-founder and distinguished technologist at Flexcompute. The company’s founder story describes him as an MIT engineering professor; the team page lists a Stanford PhD in computational and mathematical engineering.

Distinguished technologist on Flexcompute’s current published team; National Academy of Engineering member with a PhD in aeronautics and astronautics from Stanford University.

Distinguished technologist on Flexcompute’s current published team; IEEE Fellow with a PhD in electrical engineering from the University of Michigan.

Co-founder and President of Flexcompute. Oversees a company building GPU-native physics solvers and AI engineering tools including automotive aerodynamic optimization.

Co-founder and CEO of Flexcompute, a GPU-native physics simulation and engineering AI company. His company story describes founding the business with Qiqi Wang and Shanhui Fan.

Semiconductor industry executive and former Altera Chief Revenue Officer and Movella CEO. Efinix appointed him as a strategic adviser in February 2026 to support go-to-market strategy, organizational scaling and revenue growth.

Leslie Leung has served as a member of our board of directors since May 2024. He has served as a Senior Vice President at Chow Tai Fook Enterprises Limited (“CTFE”), a Hong Kong-based diversified investment holding company since February 2017. Prior to CTFE, Mr. Leung was a Strategic Investment Manager at Alibaba Group Holding Limited, and worked as an investment banker at Rothschild & Co. He served on the board of directors of Spinifex OWF Holdings Pty Ltd, Spinifex Offshore Wind Farm Pty Ltd, and other companies affiliated with CTFE, and as an alternate director for Pioneer Sail Holdings Pty Limited, Pioneer Sail Australia Pty Limited, Alinta Energy Pty Limited, and Latrobe Valley Power (Holdings) Pty Ltd. Mr. Leung holds a Bachelor of Commerce degree from the University of Auckland (New Zealand), and is a CFA charterholder and a Fellow of CPA Australia (FCPA).

Taraec Hussein has served as a member of our board of directors since February 2026. Mr. Hussein is an investment professional focused on venture capital and private equity across Southeast Asia. He has served as Senior Principal of Jelawang Capital Sdn. Bhd. since March 2025. Prior to joining Jelawang, he was Vice President of Gobi Mavcap Management (Malaysia) Sdn. Bhd. from August 2017 to August 2023. Mr. Hussein began his career in investment banking, where he focused on equity capital markets, including initial public offering pricing, rights issues and secondary placements, before transitioning to venture capital. He currently serves on the board of directors of Axiata Digital Innovation Fund Sdn Bhd and Intres Capital Partners Sdn Bhd. Mr. Hussein holds a Bachelor of Arts degree in Accounting and Finance from the University of Manchester (United Kingdom).

Mohd Rashdan Abdul Razak has served as a member of our board of directors since December 2023. Mr. Razak currently serives as Head of the Special Investment Unit in the Government Investment Companies Division of the Ministry of Finance, Malaysia. Mr. Razak began his career as a Research and Development Engineer in Japan and later in Malaysia before he joined the Malaysian Public Service Department as an Assistant Secretary in the Electricity Supply Division of the Ministry of Energy, Green Technology and Water. He has also served as the Senior Assistant Secretary in the International Relations Division of the Ministry of Higher Education and subsequently assigned to the Development Division in the same Ministry. Mr. Razak serves on the board of directors of Johor Port Berhad, Innocorp Ventures Sdn Bhd, Inno Bio Ventures Sdn Bhd and iGene Sdn Bhd. He holds a Bachelor of Electrical and Electronic Engineering from Ibaraki University (Japan), an MBA from University Malaya (Malaysia), a Diploma in Public Administration from Institut Tadbiran Awam Negara (INTAN), and a Certificate in International Studies from University of Bath (United Kingdom).

Christopher Norris has served as a member of our board of directors since May 2018, as a member of our Audit Committee since November 2018, and as Chairman of our Audit Committee from November 2018 to 2026. Mr. Norris has served as an Executive Director at Santa Clara University since November 2018, where he is also adjunct faculty, and the founding Executive Director of the Ciocca Center for Innovation and Entrepreneurship. Previously, Mr. Norris served as President, Chief Executive Officer and a board member of Alta Devices, Inc., and as a Venture Partner at BlueRun Ventures. Earlier, he served as President, Chief Executive Officer and a board member of MicroDisplay Corporation and spent 17 years at Cypress Semiconductor Corporation. Mr. Norris is the founder of Aurinko Group, an executive consulting firm. Mr. Norris has a Bachelor of Science degree in Electrical Engineering from the University of Idaho and a Master of Science degree in Computer Engineering from Santa Clara University.

Richard Sevcik has served as a member of our board of directors since May 2018, as a member of our Compensation Committee since November 2018, and as the sole member and de facto Chairman of our Compensation Committee since February 2021. Mr. Sevcik spent nearly a decade as Executive Vice President at Xilinx, Inc. After Xilinx, Mr. Sevcik founded Sevcik Consulting, which provides consulting services to semiconductor companies. Mr. Sevcik has served as a member of boards of directors and committees of publicly-traded companies, including Xilinx Alpha & Omega Semiconductors (Audit, Compensation and Governance committees) and Liquidmetal Technologies (Compensation committee). Mr. Sevcik has a Bachelor of Science degree in Engineering with a major in Physics from the University of Illinois and a Master of Science degree in Computer Science Engineering from Northwestern University.

Product designer at Liner working on AI search and research experiences.

Frontend engineer at Liner working on its search experience.

Product data analyst collaborating with product, engineering and design teams at Liner.

Co-founder and Chief Operating Officer of Liner.

Co-founded Liner and leads its AI search and research business; also publicly known as Luke Kim and Jinu Kim.

General Partner at GV focused on enterprise software, analytics and cybersecurity. Current GV source qualification: Karim Faris is published by GV as General Partner. A general partner investing in enterprise software and related technology. Existing profile emphasizes analytics and cybersecurity; current own GV directory and biography establish continued affiliation.

Retired United States Army general, former NSA director and commander of U.S. Cyber Command; founding director of Vanderbilt’s Institute of National Security. Ballistic Ventures affiliation: Retired General Paul M. Nakasone is an external adviser to Ballistic Ventures. He served for nearly four decades in the US Army and ended his military career as director of the National Security Agency and commander of US Cyber Command. His published professional profile includes founding leadership of Vanderbilt’s Institute for National Defense and Global Security and OpenAI board service. He is the same Paul M. Nakasone already profiled with WitnessAI; existing affiliations and financial references are preserved.

Co-founder and General Partner at Ballistic Ventures, formerly a founder and CTO at Fortify Software and AlienVault. Ballistic Ventures affiliation: Roger Thornton is a co-founder and General Partner at Ballistic Ventures. He previously helped build Fortify Software and AlienVault as a founder and technology leader. His career spans cybersecurity product development, company formation, mentoring and investment support. His existing WitnessAI affiliation is retained without inferring a separate personal investment.

Co-founder and General Partner at Ballistic Ventures; previously led AlienVault and AT&T Cybersecurity. Ballistic Ventures affiliation: Barmak Meftah is a co-founder and General Partner at Ballistic Ventures. He previously led AT&T Cybersecurity following its acquisition of AlienVault, which he had led as CEO. Earlier responsibilities include enterprise security at HP, product leadership at Fortify Software and product management at Oracle. He advises cybersecurity founders on company operations, product development and team-building; existing WitnessAI roles remain intact.

Leads AI research at WitnessAI on enterprise model and agent safety, prompt analysis and production AI systems; previously at SpreeAI and Valify.

Leads WitnessAI engineering; previously led engineering and product at LevelBlue/AT&T Cybersecurity and product at AlienVault.

Leads financial strategy and operations at WitnessAI; experienced adviser to venture-backed companies.

Enterprise product executive with experience at Zscaler, Symantec, NeXT/Apple and Sun.

Leads WitnessAI marketing; previously held marketing leadership roles at Imperva and Exabeam.

Leads global sales and go-to-market strategy at WitnessAI; previously CRO at Red Canary and Recorded Future.

Security and compliance executive who led product or marketing at Palo Alto Networks, Google, Symantec, ArcSight and Exabeam.

Scientific adviser leading the scientific advisory board for BrickBio’s expanded genetic code and bioconjugation platform.

Co-founder and CEO of BrickBio, developing precision biologics through protein engineering.

Biopharmaceutical research and business-development specialist whose career includes Tanabe Research Laboratories and Biogen-Idec.

Biopharmaceutical business-development and licensing specialist with experience at Arena Pharmaceuticals and Ignyta.

Oncology drug-development executive with experience spanning targeted therapies and biotechnology R&D.

Pathologist specializing in toxicologic pathology and preclinical development.

Pathologist researching anticancer biomarkers and diagnostic methods.

Antibody-drug-conjugate researcher and former ImmunoGen chemistry and biochemistry executive.

Oncologist researching lung cancer, clinical-genomic data and immunotherapy-response prediction.

Oncologist researching lung and head-and-neck cancers and targeted therapies.

Neuro-oncologist at Northwestern University whose work helped establish temozolomide with radiotherapy and tumor treating fields for glioblastoma.

Oncologist and clinical drug-development expert whose work includes pancreatic-cancer therapeutics and clinical investigations.

Former Financial Supervisory Service director general and economics graduate of Yonsei University.

Neurosurgery professor at the National Cancer Center with academic and medical-governance experience.

Medicinal-chemistry and drug-development executive with experience at Standigm, Therapex and CrystalGenomics; chemistry PhD from the University of Pittsburgh.

Drug-development CMC specialist with experience at Bridge Biotherapeutics, Iljin Inopharm, SK Biopharmaceuticals and LG Life Sciences; organic chemistry PhD from Hanyang University.

Preclinical-development scientist with life-science undergraduate and graduate degrees from KAIST.

Research and operations professional with experience at Samsung Medical Center and Ajou University; biology degrees from Yonsei University.

Pharmacist and Korean attorney whose career includes clinical research at AstraZeneca and Servier and legal leadership at MedPacto.

Biotechnology business-development director trained in health sciences and technology at Sungkyunkwan University and biomolecular sciences at the University of Michigan.

Certified public accountant with experience at NICE Investors Service and Samil PwC.

Hospital administration executive whose career includes Cheil General Hospital and Bundang CHA Medical Center.

Antibody-therapeutics researcher and former head of antibody development at AimedBio; trained in convergent medical science at Sungkyunkwan University.

Business and legal executive whose career includes Samsung Bioepis, GSK and Kim & Chang; JD from George Washington University.

Former head of R&D at AimedBio and principal scientist at Samsung Medical Center; trained in life sciences at Korea University.

Neurosurgeon and professor at Samsung Medical Center and Sungkyunkwan University specializing in brain tumors and CNS diseases; founder of AimedBio.

Biopharmaceutical finance executive and director with prior CFO experience at Pardes, Imbria and Kura Oncology.

Biologics manufacturing and technical-operations executive with prior experience at Zenas, Voyager, TESARO/GSK and Shire.

Neuroscientist at the OHSU Vollum Institute researching axon degeneration and neuron-glia signaling; his laboratory identified SARM1 as a driver of axon destruction.

Biochemist at UT Southwestern researching molecular regulation and involved in the creation of biotechnology companies including Tularik and Peloton.

Biotechnology investor at Samsara BioCapital with earlier drug-development experience at Revolution Medicines and bluebird bio. Abe Bassan is listed by Samsara BioCapital as Partner. Abraham Bassan joined at the 2017 fund launch after program-biology leadership at Revolution Medicines and drug-development work at bluebird bio.

Biotechnology physician-scientist and company builder with experience at Revolution Medicines, Third Rock Ventures and several early-stage companies.

Physician-scientist and neuroscience drug-development executive with experience at ImmunoBrain, Roche, Bristol-Myers Squibb, Lilly and Amgen.

Biotechnology investor and company builder at The Column Group, with previous research experience at KAI Pharmaceuticals.

Biotechnology business-development executive formerly with Aro Biotherapeutics, Roivant and Celgene.

Neurologist and clinical-development leader with previous experience at Amylyx, Biogen, Amgen and Annexon.

Biotechnology research leader and founding scientist at Nura Bio, with earlier drug-discovery experience at Amgen and NGM Biopharmaceuticals.

Jason Silvers is President & Chief Financial Officer of Generate:Biomedicines, overseeing the company’s financial organization and supporting enterprise scale through capital formation and strategic transactions.

Sahm is head of Business Development, Strategy, and Program and Alliance Management at Generate:Biomedicines.

Sean is the Chief Legal Officer and General Counsel for Generate:Biomedicines, overseeing all legal and compliance matters.

Laurie is the chief medical officer (CMO) of the immunology and inflammation (I&I) portfolio and is responsible for providing strategic, scientific and operational leadership for the company’s late-stage clinical development programs in I&I.

Aarif is the chief scientific officer, providing scientific and strategic leadership across the company’s platform and therapeutic pipeline.

Daria Hazuda, Ph.D., serves as Senior Vice President, Discovery Strategy at Generate:Biomedicines, leading the research team in identifying and prioritizing the best applications of The Generate Platform in vaccines and infectious diseases.

Beth Grous is the chief people officer at Generate:Biomedicines.

Gevorg Grigoryan, PhD, is co-founder & Chief Technology Officer at Generate:Biomedicines, where he leads development of the Generate Platform—an integrated system for generating new drugs on demand across diverse biologic modalities.

Dinesh is senior vice president, head of clinical drug development at Generate:Biomedicines and has responsibility for all aspects of clinical development and Investigational New Drug (IND) submissions, across immunology and oncology therapeutic areas.

Cartography Biosciences co-founder; the company identifies Chang as one of the scientists who initiated its single-cell antigen discovery approach.

Tara Arvedson, PhD, is Chief Scientific Officer at Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome.

Janine Schuurman, PhD, is a scientist, inventor, and biotech leader whose career centers around the antibody molecule as a biological source of inspiration and therapeutic modality.

Carl June is a physician scientist and the Richard W.

Kevin Parker is the CEO and co-founder of Cartography Biosciences.

Erin Daruszka is our fractional Head of People focused on helping us be an amazing place for people to work and develop.

David Kugler is Vice President of Research & Development at Cartography and is the Global Asset Lead for Cartography’s lead program CBI-1214.

Dan Rock is Chief Scientific Officer at Cartography, where he leads scientific operations and aligns strategy with the company’s mission.

Chester Wong is Senior Vice President, Head of Business Development at Cartography.

Annie Winterhall is the Head of Clinical Operations at Cartography.

Leads Rebellions’ global commercial growth and US expansion; previously led customer and commercial functions at SambaNova and held senior roles at Oracle.

Rebellions co-founder and CEO, with a background in AI and system semiconductor engineering and a doctorate from MIT.

Colin Born serves as Vice President, Finance & Strategy at Delos Data.

Prem Jonnalagadda serves as Vice President, Marketing & Business Development at Delos Data.

Rachel Everman serves as Chief of Staff at Delos Data.

Alain Gravel serves as Vice President, Engineering at Delos Data.

Dan Daly serves as Chief Technology Officer & Co-founder at Delos Data.

Ed Doe serves as Chief Executive Officer & Co-founder at Delos Data.

Savaughn Christman is published by Matter Venture Partners as Executive Admin, Operations & Platform.

Natalia Korenev is published by Matter Venture Partners as Executive Admin, Investment Team.

Hillary Sherpa is published by Matter Venture Partners as Executive Admin, Managing Partner.

Chelsea Dvorak is published by Matter Venture Partners as Head of Operations.

Bing Gordon is published by Matter Venture Partners as Advisor.

Ivy Qiu is published by Matter Venture Partners as Europe Representative.

Tetsuya Umeki is published by Matter Venture Partners as Japan Advisor.

Sherry Tsai is published by Matter Venture Partners as Taiwan Representative.

Pragna Paranji is published by Matter Venture Partners as Chief of Staff.

Zachary Cefaratti is published by Matter Venture Partners as Operating Partner & Head of Middle East.

Cross-border technology investor and Chip One Stop founder supporting Matter’s investment activities and industrial relationships in Japan.

Neurologist researching progressive multiple sclerosis and leading veterans’ MS care.

Neurologist and founder of the MS Center for Innovations in Care.

Neurologist and physical therapist researching gait, mobility and falls in multiple sclerosis.

Neurologist specializing in neuroimmunology and multiple sclerosis.

Medtech and digital-health commercial leader; formerly held leadership roles at Resmed and Aria Health.

Technology entrepreneur who founded Cionic in 2018 to develop adaptive wearable mobility assistance inspired by his daughter’s cerebral palsy.

Impact investor and business founder whose Sorenson Impact platform supports Enable Ventures.

Investor with a background in disability public policy, accessible product strategy and business.

Early-stage investor with a neuroscience PhD from the University of Utah.

Also known as Gina Kline; investor and former civil-rights lawyer focused on inclusive disability technology.

Amanda White is listed by Ascension Investment Management, LLC as Chief Compliance Officer & Associate General Counsel. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Todd Turall is listed by Ascension Investment Management, LLC as General Counsel & Chief Operating Officer. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Erin Carnes is listed by Ascension Investment Management, LLC as Senior Investor Relations Associate. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Kayla Zalis is listed by Ascension Investment Management, LLC as Associate Director of Investor Relations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jessica Cook is listed by Ascension Investment Management, LLC as Managing Director of Business Development. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred. The2024 RCRI speaker biography says she leads business development and client relationships, joined AIM in2012, previously worked at Stark Investments and Strong Capital Management, and earned a finance degree at the University of Wisconsin–La Crosse.

Jill Barlow is listed by Ascension Investment Management, LLC as Senior Executive Assistant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Nakeeta Miller is listed by Ascension Investment Management, LLC as Senior Executive Assistant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Cherie Browning Baur is listed by Ascension Investment Management, LLC as Accountant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Mark Duncan is listed by Ascension Investment Management, LLC as Associate Director of Performance. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Nathan Johns is listed by Ascension Investment Management, LLC as Senior Associate of Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jacob Styve is listed by Ascension Investment Management, LLC as Senior Accountant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Melinda Beuttel is listed by Ascension Investment Management, LLC as Senior Accountant. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jonathan Gierich is listed by Ascension Investment Management, LLC as Director of Finance & Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Matthew Goessling is listed by Ascension Investment Management, LLC as Senior Director of Finance & Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Timothy McDowell is listed by Ascension Investment Management, LLC as Managing Director of Finance & Investment Operations. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Alex Poynter is listed by Ascension Investment Management, LLC as Senior Investment Analyst. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Zachary Rasure is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Abhishek Rane is listed by Ascension Investment Management, LLC as Associate Director of Strategy & Risk Management. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Scott Schleiffarth is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Jingwan Chen is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred. A legacy firm biography reports joining AIM in2015, previous investment roles at Edward Jones and T Rowe Price, a mathematics/economics degree from Kenyon College, and CFA/CAIA credentials.

Tyler Blickhan is listed by Ascension Investment Management, LLC as Associate Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Vincent Stegman is listed by Ascension Investment Management, LLC as Managing Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Maurice Perry is listed by Ascension Investment Management, LLC as Managing Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Joshua Kaplan is listed by Ascension Investment Management, LLC as Managing Director of Investments. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Michael LeVar is listed by Ascension Investment Management, LLC as Managing Director of Strategy & Manager Research. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

Michael Griswold is listed by Ascension Investment Management, LLC as Deputy Chief Investment Officer. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred.

David Erickson is listed by Ascension Investment Management, LLC as Chief Investment Officer. AIM is a St. Louis institutional investment adviser serving faith-based organizations across public, alternative and private markets under Catholic socially responsible investing guidelines. This profile records the firm’s published directory role; no undisclosed appointment date or personal investment is inferred. He joined the Ascension investment office in2009 and previously served as CIO of the University of Wisconsin Foundation. His FOCUS St Louis biography reports an economics degree from Wheaton College and CFA credential.

Kimberly Reed is a Takeda external director and Audit and Supervisory Committee member. Her experience includes leadership of the US Export-Import Bank, the Community Development Financial Institutions Fund and public-policy and finance roles at the US Treasury and other organizations.

Bruce Broussard joined Takeda’s board and Audit and Supervisory Committee in June 2026. His leadership experience includes Humana, US Oncology and McKesson. Takeda’s published biography also lists his interim CEO role at HP beginning in February 2026.

Koichiro Kimura is a Takeda external director and head of its Audit and Supervisory Committee. His background includes representative executive leadership at PricewaterhouseCoopers Aarata, now PricewaterhouseCoopers Japan.

Miki Tsusaka joined Takeda’s board as an external director in June 2023. She has served as Microsoft Japan President since February 2023 and previously held senior partner, marketing and executive-committee leadership roles at Boston Consulting Group.

Paul Stoffels is a Takeda external director with pharmaceutical research and development leadership experience. His career includes leading pharmaceutical R&D and serving as vice chair and chief scientific officer at Johnson & Johnson.

Masami Iijima is a Takeda external director and chair of its board meeting. He has chaired the board meeting since June 2022. His career includes senior executive and representative-director leadership at Mitsui & Co.

Teresa Bitetti leads Takeda’s Global Oncology Business Unit, overseeing its international cancer medicines portfolio and commercial operations. She holds an MBA from the University of Virginia’s Darden School and a degree from Wellesley College.

Rhonda Pacheco leads Takeda’s US Business Unit and serves as US Country Head. Her portfolio spans gastroenterology, neuroscience, plasma-derived therapies and rare diseases. She holds a Duke Fuqua MBA and Doctor of Pharmacy degree from the University of Rhode Island.

Ramy Riad leads Takeda’s Plasma-Derived Therapies Business Unit. He holds an MBA in finance from Southern New Hampshire University and an accounting and business-administration degree from Cairo University.

Nicola Greenway is Takeda Chief Human Resources Officer, leading its global people function. Her qualifications include science degrees, business and management studies, employment law at the University of Surrey and an executive MBA from ENPC Paris and the University of Edinburgh.

Natalie Furney joined Takeda as Global General Counsel in April 2025. Her professional work includes legal leadership, continuous improvement and talent development, and she has participated in international trade-sanctions compliance forums.

Milano Furuta serves as Takeda Chief Financial Officer and a board director. He holds a Wharton MBA and a degree in international affairs from Hitotsubashi University in Japan.

Marcello Agosti is Takeda’s interim head of strategy and portfolio development. He leads business development, mergers and acquisitions and corporate development. He holds an Oxford MBA and a business-administration degree from Bocconi University.

Lauren Duprey is Takeda Chief Transformation Officer, responsible for connecting transformation initiatives across the company, including artificial intelligence programs. She holds a biology degree from Harvard University and an MBA from MIT Sloan.

Jennifer Smoter leads Takeda’s communications and governance organization, including corporate communications, brand, sustainability and coordination with its board. Her remit includes CEO chief-of-staff responsibilities and company reputation and stakeholder engagement. She is based in Boston.

Giles Platford leads Takeda’s International Business Unit, overseeing markets outside the United States. He focuses on commercial portfolio growth and international operations and is based in Tokyo. He holds a business and marketing-management degree from Oxford Brookes University.

Gabriele Ricci is Takeda Chief Data and Technology Officer, appointed in February 2022. He leads its data, digital and technology transformation. He holds an MBA from MIB Trieste School of Management and an engineering degree from the University of Rome Tor Vergata.

Elaine Shannon leads Takeda’s global supply and quality organization, covering internal and partner manufacturing, supply-chain operations and product quality. She holds a master’s degree in pharmaceutical manufacturing technology and an undergraduate qualification in good manufacturing practices.

Awny Farajallah is Takeda Chief Medical Officer. He joined in July 2021 as head of global oncology medical affairs and brings experience in clinical research, development and medical affairs. He earned his MD at Cairo University and undertook internal-medicine and infectious-disease training in the United States.

Asuka Miyabashira leads Takeda’s Japan Pharma Business Unit and serves as Japan Country Head. She joined in 2004 and has held marketing, medical and commercial leadership positions in Japan and internationally, including serving as country manager in Vietnam.

Andrew Plump leads research and development at Takeda and serves on its board. His training combines clinical medicine and cardiovascular genetics. He holds an MIT undergraduate degree, UCSF MD and Rockefeller University PhD, with residency and medical-genetics fellowship training at UCSF.

Julie Kim became Takeda President, CEO and Representative Director on 24 June 2026. She joined through the Shire acquisition in 2019 and previously led the plasma-derived therapies and US business units. Earlier experience includes Baxter, Baxalta and Shire. She holds a Kellogg MBA and Dartmouth economics degree.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Lead Independent Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Board Director at Pfizer, verified in the company current public leadership directory and individual biography. This is a board oversight appointment; no corporate management or personal investment attribution is inferred.

Pfizer board director and founder and managing partner of GenNx360 Capital Partners. Previously founded Blaylock & Company and held senior investment-banking positions at UBS, PaineWebber and Citicorp. His Pfizer role is board oversight, separate from management or personal investments.

Chief People Experience Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief Global Supply and Quality Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief U.S. Commercial Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief Legal Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Head of Strategy, Executive Operations, Counsel to the CEO at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief Information Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Chief International Commercial Officer, Executive Vice President at Pfizer, verified in the company current public leadership directory and individual biography. Member of Pfizer Executive Leadership Team, responsible for the stated operating function.

Interim CFO and Executive Vice President of Pfizer, effective August16,2026. Previously senior vice president of finance for its Global Biopharmaceuticals business. Has more than25years in global pharmaceutical finance. Pfizer’s June2026SECfiling states she joinedPfizerin2005; the websitebiography associates her arrival with the2009Wyethacquisition, so the SECemployment chronology is used for that detail.

Chief Scientific Officer and President, Research & Development of Pfizer, directing research across therapeutic areas and its business-development organization. Previously Chief Oncology Officer and founding director of the UCL Cancer Institute; trained as a medical oncologist.

Chairman and CEO of Pfizer. Became CEO in January2019. Veterinary medicine doctorate and biotechnology-of-reproduction PhD from Aristotle University. Current primary biography describes AI as central to Pfizer medicine discovery, development and manufacturing.

Joe Tobias is Chief Financial Officer for Corporate Responsibility and Morgan Health at JPMorganChase, with additional oversight of the American Dream Initiative. He has held financial-control, risk-reporting and sustainability-reporting roles across more than eighteen years at JPMorganChase and is treasurer and board member of its Foundation. He holds a finance degree from Pennsylvania State University.

Brooke Thurston is Chief of Staff and Head of Communications and Policy at Morgan Health. She previously held chief-of-staff and communications responsibilities at Haven, the JPMorganChase, Amazon and Berkshire Hathaway joint venture, and worked on Capitol Hill and at VOX Global. She holds a government degree from Colby College.

Jeffrey Ries, also published as Jeff Ries, is Partner and Co-Head of Investments at Morgan Health. His official current biography lists board service at Fuze Health and Thyme Care. He previously led venture investing at Healthbox, including the DaVita Venture Fund and Intermountain Health Care Innovation Fund, and worked at Oxeon Partners, Sandbox Industries and LaSalle Investment Management. He holds degrees from Northwestern and Harvard Business School.

Dan Mendelson is CEO of Morgan Health. He founded and led Avalere Health and previously served as Associate Director for Health at the Clinton administration’s Office of Management and Budget. His current official biography lists board service at Champions Oncology and the Peterson Center on Healthcare and adjunct teaching at Georgetown McDonough. He holds degrees from Oberlin and Harvard Kennedy School.

Trey Hollern is Executive Director and Head of External Communications at Morgan Health. His prior communications roles included Becton Dickinson, CVS Health Caremark, APCO Worldwide and Porter Novelli. He holds journalism and integrated-marketing-communications degrees from West Virginia University.

Dan Hartman is Partner and Co-Head of Investments at Morgan Health. His current official biography identifies board service at Centivo and Cortica. He previously led analytics and transformation at Beacon Health Options, advised clients at Boston Consulting Group, and worked in healthcare investment banking at Goldman Sachs. He served seven years in US Army Special Forces and holds bachelor’s and master’s degrees from Georgetown. This is the healthcare investor, rather than the similarly named medical-research executive.

Katie Bobroske leads Morgan Health’s Data Science and Research team, developing healthcare data-warehouse insights for JPMorganChase’s health plan and the employer-insurance market, supporting investment diligence and portfolio companies, and engaging on healthcare data and AI policy. Earlier roles included McKesson, Evolent Health, the UK National Health Service and Haven. She earned a PhD and MPhil at Cambridge Judge Business School and an operations-research degree at Cornell.

A. James Khodabakhsh, MD, is a director of Amydis. An ophthalmic surgeon, he specializes in cataract, glaucoma and refractive procedures and has worked in clinical leadership and surgical-center management in Beverly Hills.

Jerre Stead is a director of Amydis and founder and chairman of Stead Impact Ventures. He formerly led Clarivate and IHS Markit and has served as CEO or chairman of numerous public companies; his philanthropic work includes Alzheimer's research. Jerre Stead serves on Spinogenix’s board and chairs Stead Impact Ventures. His earlier business leadership includes Clarivate and IHS Markit, alongside philanthropic support for research into Alzheimer’s disease. Jerre Stead is co-founder and board chair of ALZpath, a blood-based Alzheimer’s diagnostics company founded in2020.

Philip Werthman, MD, MMH, serves on Amydis' Scientific Advisory Board. A microsurgeon and biotech investor, he founded Merkava Holdings and has advised companies in biotechnology, pharmaceuticals and aerospace. His training includes neuropsychology, medicine and military history. He is Founder and President of Merkava Holdings, the investment arm of the Philip E. Werthman Trust, supporting early and mid-stage technology and life-sciences companies through investment and international business development.

Robert Zamboni, PhD, serves on Amydis' Scientific Advisory Board. A medicinal chemist with more than four decades in drug discovery, he worked on Singulair and other medicines at Merck Frosst and later founded drug-discovery consulting business ZCS.

Jeffrey Kordower, PhD, serves on Amydis' Scientific Advisory Board. His research specializes in Parkinson's disease, related neurodegenerative disorders and nonhuman-primate models. He helped establish the ASU-Banner Neurodegenerative Disease Research Center.

Jose Pulido, MD, MS, MBA, MPH, serves on Amydis' Scientific Advisory Board. His research spans vitreoretinal inflammation and infection, retinal degeneration, stem cells and immunotherapies; his career includes translational research at Mayo Clinic and Wills Eye Hospital.

Irene Litvan, MD, serves on Amydis' Scientific Advisory Board. Her expertise includes Parkinsonian disorders, cognitive neuroscience and epidemiology, including work to improve clinical diagnostic criteria for neurodegenerative movement disorders.

Eric M. Reiman, MD, serves on Amydis' Scientific Advisory Board. A psychiatrist and brain imaging researcher, he studies Alzheimer's biomarkers, APOE genetics and prevention and co-founded the Alzheimer's blood-test company ALZPath. Eric M. Reiman is ALZpath co-founder and scientific adviser, and founding CEO of Banner Alzheimer’s Institute. His research spans brain imaging, Alzheimer’s genetics, blood biomarkers and prevention.

SriniVas R. Sadda, MD, serves on Amydis' Scientific Advisory Board. His research applies automated image analysis and advanced retinal imaging to ophthalmology, drawing on neuro-ophthalmology and medical retina training at Johns Hopkins.

Steven D. Schwartz, MD, serves on Amydis' Scientific Advisory Board. His research concerns macular degeneration, retinopathy of prematurity, diabetic eye disease and the development of imaging, surgical and drug-delivery technologies.

Alfredo Sadun, MD, PhD, serves on Amydis' Scientific Advisory Board. His work centers on neuro-ophthalmology and optic nerve disorders, with training at MIT and Harvard and a career in academic ophthalmology.

David S. Boyer, MD, serves on Amydis' Scientific Advisory Board. A retinal clinician and surgeon, he helped establish Retina-Vitreous Associates Medical Group in Los Angeles and has investigated retinal disease treatments in clinical trials.

Alex Huang, MD, PhD, is Chief Medical Advisor at Amydis and an ophthalmologist specializing in glaucoma and cataract surgery. His research addresses aqueous humor outflow, glaucoma surgical outcomes and ocular changes during spaceflight.

Vicki P. Raeburn, PhD, is Chief Data Science Officer at Amydis. Her career includes leadership of analytical and information operations at IHS, Dun & Bradstreet, Mergent and other financial information businesses. She earned a doctorate in cognitive psychology at Yale University.

Kerri Nelson is Chief Operating Officer at Amydis. She has led data strategy, products, customer operations and integration at Dun & Bradstreet, IHS Markit and Clarivate, and founded customer-experience analytics company CustomersFirst Now.

Ali Tafreshi is Chief Technology Advisor at Amydis. His experience spans glaucoma, neuro-ophthalmology, retinal conditions and clinical trials, including research at the Hamilton Glaucoma Research Center and product management and clinical affairs at Heidelberg Engineering. Topcon Healthcare CEO, explicitly retained in the October 6, 2026 Oku launch announcement. Also CEO of the separately launched Oku Digital Health and global EyeCare chief strategy officer at parent Topcon Corporation. His former combined CEO/president title was superseded when Lance Patton became president in April 2026.

Stella Sarraf founded Amydis in 2013 and leads it as CEO and a director. She trained in organic chemistry at Columbia University and biochemistry and molecular biology at UC Berkeley. Her prior experience includes Merck chemistry and healthcare venture investing at Foresite Capital and Prospect Venture Partners; she also founded Spinogenix in 2016. Stella Sarraf founded Spinogenix in 2016 and serves as CEO and a director, alongside her leadership of Amydis. Her background combines medicinal chemistry, pharmaceutical operations, venture investment and company formation.

Stephen Petersen is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Investment Committee Advisory Member (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Paul Leff is listed by the University of Wisconsin Foundation/Wisconsin Foundation and Alumni Association in these current roles: Investment Committee Advisory Member (WISIMCO investment division). WISIMCO is the operational name of the Foundation’s investment division, supporting investment stewardship for UW–Madison.

Michael Knetter is an Investment Committee Advisory Member of the University of Wisconsin Foundation’s WISIMCO investment division and serves as a senior adviser on the investment team. He previously served as WFAA president and CEO from 2010 through 2024; Alisa Robertson became CEO in January 2025.